CalciMedica Inc

Earnings data Q3 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CalciMedica, Inc. operates as a biopharmaceutical company. It focuses on developing therapies for life-threatening inflammatory diseases. The firm's product candidate Auxora helps in treating acute pancreatitis and asparaginase-associated pancreatitis. The company was founded by Kenneth A. Stauderman and Gonul Velicelebi in 2007 and is headquartered in La Jolla, CA.

Auxora ™  showed a 53% reduction in days in hospital, a 40% reduction in intensive care unit (ICU) days and eliminated the need for total parenteral nutrition (TPN) LA JOLLA, Calif. , Nov. 2, 2023 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic diseases, today announced that there will be a presentation of data from the initial cohort of the CRSPA study of Auxora™ (zegocractin) in asparaginase-induced pancreatic toxicity (AIPT) in a poster presentation at the 65th Annual American Society of Hematology (ASH) Meeting & Exposition being held December 9-12, 2023 in San Diego, CA.

CalciMedica Announces Presentation of Initial Data from the CRSPA Study of Auxora at the 65th Annual ASH Meeting & Exposition

LA JOLLA, Calif. , Sept. 6, 2023 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced that Rachel Leheny, Ph.D.

CalciMedica Announces Upcoming Presentations and Events in September

LA JOLLA, Calif. , Aug. 31, 2023 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced that it will host a virtual clinical experts event on Thursday, September 21, 2023, from 10:30 a.m.

CalciMedica to Host Acute Pancreatitis Clinical Experts Event on September 21, 2023

CARPO top-line data expected in 1H2024 CARPO enrolling in over 30 sites in the US and India LA JOLLA, Calif., Aug. 09, 2023 (GLOBE NEWSWIRE) -- CalciMedica Inc. (“CalciMedica”) (NASDAQ: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced that its ongoing CARPO trial, a Phase 2b trial evaluating Auxora™ for the treatment of acute pancreatitis (AP) with accompanying systemic inflammatory response syndrome (SIRS), was expanded to clinical research sites in India and that the first patient has been enrolled there.

CalciMedica Announces First Patient Enrolled in International Expansion of CARPO Trial of Auxora™ in Acute Pancreatitis (AP)

LA JOLLA, Calif., June 12, 2023 (GLOBE NEWSWIRE) -- CalciMedica Inc. (“CalciMedica”) (OTCQB: CALC), a clinical-stage biopharmaceutical company focused on developing therapies for life-threatening inflammatory diseases with high unmet need, today announced that The Nasdaq Stock Market LLC has approved CalciMedica's application for the relisting of the Company's common stock on the Nasdaq Capital Market. The Company's common stock is expected to commence trading on the Nasdaq Capital Market at the opening of trading on Wednesday, June 14, 2023, under the ticker symbol “CALC”. CalciMedica's common stock will continue to trade on the OTCQB until market close on the date before listing on the Nasdaq Stock Market under the ticker symbol "CALC".

CalciMedica Announces Relisting on Nasdaq

Results support the initiation of clinical studies to assess Orai1 inhibition in patients with recurrent acute pancreatitis (RAP) and early CP

CalciMedica Announces Publication of Preclinical Data in Journal of Clinical Investigation (JCI) Insight Supporting the Development of CRAC Channel Inhibitors for Chronic Pancreatitis (CP)

BOSTON, May 23, 2023 (GLOBE NEWSWIRE) -- Life Biosciences (“Life Bio”), a biotechnology company advancing innovative cellular rejuvenation platforms to reverse diseases of aging and injury and ultimately restore health for patients, today announced the appointment of Ming Yang, Ph.D., as Senior Vice President of Research and Development. Dr. Yang will be responsible for overseeing the company's research and development efforts and advancing its pipeline of cellular rejuvenation candidates.

Life Biosciences Expands Team with the Appointment of Ming Yang, Ph.D., as SVP of Research and Development

Raven Jaeger, M.S. named Chief Regulatory Officer and Andrew Cunningham, M.D., MRCPI, named Senior Vice President, Clinical Development Raven Jaeger, M.S. named Chief Regulatory Officer and Andrew Cunningham, M.D., MRCPI, named Senior Vice President, Clinical Development

CalciMedica Expands Executive Team with New Appointments

LA JOLLA, Calif., May 15, 2023 (GLOBE NEWSWIRE) -- CalciMedica Inc. (“CalciMedica”) (OTCQB: CALC), a clinical-stage biopharmaceutical company focused on developing therapies for life-threatening inflammatory diseases with high unmet need, today reported financial results for the first quarter ended March 31, 2023.

CalciMedica Reports First Quarter 2023 Financial Results and Provides Clinical & Corporate Updates

- CalciMedica common stock to commence trading on Nasdaq Global Market on March 21, 2023 under ticker symbol “CALC” - Cash and cash equivalents of approximately $34 million as of merger close expected to support operations into the second half of 2024 - Phase 2b results in acute pancreatitis for lead product candidate Auxora™  expected in Q4 2023 - CalciMedica to host Research and Development Event on April 27, 2023

CalciMedica Announces Closing of Merger with Graybug Vision and Concurrent Private Placement

News for CalciMedica Inc Stock (CALC)